Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

The bioengineering company Ossium Health has created a new program that offers deep-frozen bone marrow from deceased organ ...

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

Positive preliminary outcomes were reported for the first leukemia patient treated with Ossium Health's organ donor bone ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia.

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...